Table 1.
Demographics of study cohort for RECIST-evaluable tumors
| Patient characteristics | N |
|---|---|
| Number of patients | 26 |
| Sex | |
| Male | 22 |
| Female | 4 |
| Median age at time of treatment (range) | 68 years (54–96) |
| Number of MCC metastases treated with 8Gy SFRT evaluable by RECIST | 92 |
| Low-risk patients (no. tumors) | 13 (32) |
| High-risk patients (no. tumors) | 13 (60) |
| Median tumor size (range) | 4 cm (1–19) |
| Characteristics of HR patients | No. patients (tumors) |
| Immunosuppressive illness (myelodysplasia) + medication (chronic methotrexate) | 1 (3) |
| Medications (chronic methotrexate, anti-rejection medications) | 2 (4) |
| Immunosuppressive illness (CLL or myelodysplasia) + prior chemotherapy | 2 (6) |
| Only prior chemotherapy | 8 (47) |
| Median interval between MCC diagnosis and SFRT (range) | 568 (24–1987) |
| Low-risk patient tumors | 669 (56–1987) |
| High-risk patient tumors | 413 (24–429) |
| Median interval between first metastatic MCC lesion and SFRT (range) | 207 (9–813) |
| Low-risk patient tumors | 113 (9–445) |
| High-risk patient tumors | 366 (35–813) |
| Patient outcomes | |
| Median follow up time from SFRT among all living patients (range) | 277 days (104–699) |
| Low-risk patients | 277 days (104–499) |
| High-risk patients | 256 days (175–699) |
| Median time to treated lesion progression in days (no. of treated tumors that progressed) | |
| Low-risk tumors (3 of 32) | 193 days |
| High-risk tumors (17 of 57) 1 | 71 days |
1
Among 60 high-risk tumors, treated lesion progression data was available only for 57 tumors. For remaining 3 tumors treated lesion progression was unknown.